Immunocore (IMCR) announces strategic priorities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
January 10, 2025 7:00 AM ESTÂ Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration
Enrolling three Phase 3 trials across multiple melanoma indications potential data readouts beginning with TEBE-AM in 2026
Enrolling Phase 1/2 trial with brenetafusp combinations in ovarian and lung cancer; ongoing dose escalation with IMC-R117C (PIWIL1) and IMC-P115C (PRAME-A02-HLE)
Presenting initial HIV Phase 1 MAD data in the first quarter 2025
Progressing first-in-class, tissue-tethered autoimmune platform Type 1 diabetes candidate on track for CTA submission in 2025; first... More
